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Abstract
Background: To assess the clinical significance and prognostic impact of extranodal metastasis (EM) in gastric carcinoma
and establish an optimal classification in the staging system.
Methodology/Principal Findings: A total of 1343 patients with gastric carcinoma who underwent surgical resection were
recruited to determine the frequency and prognostic significance of EMs. EMs were divided into two groups (EM1 and EM2)
and then incorporated into the 7
th edition UICC TNM staging system. EMs was detected in 179 (13.3%) of 1343 patients who
underwent radical resection. Multivariate analysis identified EMs as an independent prognostic factor (HR=1.412,
95%CI=1.151–1.731, P,0.001). After curative operation, the overall survival rate were worse in patients with $3 cases of EM
(EM2) than those with the number of 1 and 2 cases (EM1) (P,0.001). Survival of patients with EM1 was found almost
comparable to that of N3 stage (P=0.437). Survival of patients with EM2 showed similar to that of stage IV patients
(P=0.896). By using the linear trend X
2, likelihood ratio X
2, and Akaike information criterion (AIC) test, EM1 treated as N3
stage and EM2 treated as M1 stage performed higher linear trend X
2 scores, likelihood ratio X
2 scores, and lower AIC value
than the 7
th edition UICC TNM staging system, which represented the optimum prognostic stratification, together with
better homogeneity, discriminatory ability, and monotonicity of gradients.
Conclusions/Significance: EMs might be classified based on their number and prognostic information and should
incorporate into the TNM staging system.
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Introduction
Histological examination of dissected nodal structures may
disclose the presence of nodules of tumors that are not contained
with recognizable lymph node tissue. This kind of cancer deposit
so called Extranodal Metastases (EMs), which comprising cancer
cells in soft tissue discontinuous with the primary lesion without
evidence of residual lymph node tissue, is found during routine
examination of about 10–28 percent of resected gastric carcinoma
specimens. The presence of EM has also been identified as a
prognostic factor [1,2].
It has long been ambiguous whether such involvement should
be treated as a T, N, or even M factor, or should be excluded from
consideration in determining tumor stage in recent years. In the
American Joint Committee on Cancer (AJCC)/International
Union Against Cancer (UICC) 5th and 6th edition TNM staging
system, this type of tumor spread should be regarded as lymph
node metastasis of the nodule with the form and smooth contour
of a lymph node, but should otherwise be regarded as part of the
primary tumor [3,4]. In the year of 2009, UICC published the 7th
edition TNM classification of malignant tumors for gastric
carcinoma. According to the 7th edition classification, this type
of metastatic nodules in the fat adjacent to a gastric carcinoma,
without evidence of residual lymph node tissue, are considered
regional lymph node metastases, but nodules implanted on
peritoneal surfaces are considered distant metastases [5]. While
this type of definition is still comprehensive and ambiguous. For
example, should a case of EMs be deemed as a metastatic lymph
node, or should a case of EMs be deemed as an upgraded N stage?
With different features of EMs such as number or shape, the
prognostic significance maybe still variable. Furthermore, how to
combine this type of metastatic nodules into TNM staging system
is also unclear. Up to date, there has been few studies focused on
the significance through convincing analysis in gastric carcinoma
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e19557[2], and there are even less data on the optimal categorization of
such foci. Nevertheless, an optimal categorization should heighten
the value of the TNM classification as a prognostic staging system.
Therefore, the aim of the present study was to assess the
incidence, the relationship with other clinicopathologic factors,
and the prognostic significance of EMs in patients with gastric
carcinoma. In addition, to investigate the possible classification of
EMs, we classified them into several different categories based on
the different survival outcomes and determined whether EMs
should be combined into TNM staging system or into which kind
of staging. Finally, validation and comparison of the homogeneity,
discriminatory ability and monotonicity of gradient of the new
classification with the 7th edition TNM staging system were
performed.
Methods
Participants
Clinicopathological data from 1580 cases of gastric cancer
patients who underwent surgical resection from Jan. 1994 to Dec.
2006 at Sun Yat-sen University Cancer Center were analyzed
retrospectively. The routine postoperative pathological results
included tumor size, histological type, margin, adjacent tissues and
neighboring organs, lymphatic/venous invasion, retrieved lymph
nodes, metastatic lymph nodes, and pTNM staging. The eligibility
criteria included histologically confirmed R0 resection, which was
defined as no macroscopic and microscopic residual tumor and a
postoperative survival time of $3 months. Patients with distant
metastases and carcinoma of the gastric stump after gastric
resection for benign disease were excluded from the study. Among
the potential participants, 106 had distant metastases (liver, lung,
ovary, abdominal or pelvic cavity dissemination), 41 underwent
R1 or R2 resection, 13 had distant lymph node metastases
(retropancreatic, mesenteric, duodenohepatic ligament or para-
aortic lymph node), 15 died less than 3 months after resection, and
62 were lost to follow-up. Thus, 237 patients were excluded and
1343 patients were recruited.
Surgical procedures
D2 lymphadenectomy was performed by experienced surgeons
following the JGCA guidelines [6]. All resected specimens were
fixed in 10 percent formalin, embedded in paraffin, and stained
with haematoxylin and eosin. All solid structures in adipose
connective tissue resected with the stomach were retrieved,
including the lymph nodes and any areas of EMs. EMs were
defined as the presence of cancer cells in soft tissue that was
discontinuous with the primary lesion or in peri-stomach soft tissue
distinct from the lymph node.
Ethics statement
The protocol was approved by Sun Yat-sen University Cancer
Center review board in keeping with Chinese bioethical
regulations. All patients gave a written informed consent before
participating in the study.
Follow up
Postoperative follow-up included clinical and laboratory
examinations every 3 months for the first 2 years at our outpatient
department, every 6 months from the third to fifth years, and
annually thereafter until at least 5 years after the operation or until
the patient died, whichever came first. Overall patient survival,
defined as the time from operation to death or last follow-up, was
used as a measure of prognosis. The follow-up was closed in May
2010. The median follow-up for the entire cohort was 50 months
(range 3–197 months).
Statistical Analysis
Mann–Whitney U test and X
2 tests were used where appropriate
to compare the distribution of individual variables between groups.
The 5-year survival rate was calculated using the Kaplan–Meier
method. Statistical comparisons of different factors were made with
the log-rank test. In multivariate analysis, forward stepwise regression
analysis was performed with a Cox proportional hazards model. A
two-tailed P value of #0.05 was considered statistically significant.
To compare the redefinitions of the T, N, and M categories with
the 7th edition TNM staging system, the likelihood ratio X
2 test
related to the Cox regression model was used for measuring
homogeneity. The discriminatory ability and monotonicity of
gradient assessments were measured with the linear trend X
2 test
[6,7,8]. The Akaike information criteria (AIC) value within a Cox
proportional hazard regression model also was calculated for each
category to measure its discrimination ability and identify the
optimal categorization of EMs that afforded the T, N, and M
stages the highest power of discrimination of survival outcome for
each stage [9]. The AIC (AIC=226Log likelihood +26No. of
parameters in the model) is an estimate of the measure of fit of a
model to a given set of data. The model of choice achieves
parsimony with maximum likelihood and the lowest value of AIC,
indicating the smallest loss of information for predicting outcome
[10,11,12,13]. All statistical analyses were performed using SPSS
software version 18.0 (SPSS Inc., Chicago, IL).
Figure 1. Haematoxylin and eosin staining shows extranodal metastasis (EM) in gastric carcinoma. Tumor cells are scattered into the
resected adipose connective tissue around the stomach distinct from the metastatic lymph node. 1A: Original magnification 6100, arrow indicates
the EM. 1B: Original magnification6400.
doi:10.1371/journal.pone.0019557.g001
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Of the 1343 patients, 902 (67.2%) were males, and 441 (32.8%)
were females. The mean age of the patients was 56.4611.9 years
(range 17–85 years). The overall 5-year survival rate for all
patients was 55.9%, and 730 patients were alive when our follow-
up was completed.
Stage distribution included 192 (14.3%) patients with stage I,
408 (30.4%) patients with stage II, 743 (55.3%) with stage III
according to the 7
th edition TNM staging system [5]. Consider-
ation of the possible origin for EMs excluded from implantation on
peritoneal surfaces, we investigated the incidence of EMs for 1343
cases of patients with potential radical resection.
Overall, EMs were detected in 179 (13.3%) of the 1343 patients
and in 359 (1.8%) of the 20,047 nodules retrieved as ‘lymph
nodes’. In the 179 patients with EM, 102 patients were detected
with 1 EM, 29 patients with 2 EMs, and 48 patients with $3 EMs.
The mean number of metastases of this type was 1.44 (median
1.37, range 1–7). Figure 1 shows an example of EMs.
The incidence of EMs was significantly higher in patients with
total gastric carcinoma, larger tumors (.5.0 cm) and in those with
poorly and undifferentiated carcinoma (G3/G4). EMs was found
significantly more common in tumors with lymphatic/venous
invasion. Additionally, patients with EMs had a significantly
deeper tumor invasion (T4a and T4b) and more number of lymph
node metastases (N3). Tumor stage was III in 141 (78.8%) of 179
patients with EMs. (Table 1)
Regarding survival, univariate analysis was performed in 1343
patients who underwent potentially radical resection. Variables
including age, tumor location, size, differentiation, lymphatic/
venous invasion, EMs, pT, pN, and TNM staging correlated well
with the patients’ life expectation. In the multivariate analysis,
EMs emerged as an independent prognostic factor for survival
together with the aforementioned factors (HR=1.412,
95%CI=1.151–1.731, P,0.001). (Table 2)
Positive EMs were significantly associated with a shorter
survival time (P,0.001) (Fig. 2A). Analysis of patients grouped
according to the number of EMs revealed that patients with EMs
$3 had an even worse postoperative survival than that of
patients with the number of EMs less than 3. The 5-year survival
rate of patients with the number of EMs as 1, 2, and $3w e r e
35.2%, 27.6%, and 6.8% (P=0.337 and 0.001, respectively)
(Fig. 2B).
In order to incorporate the EMs into the T, N, and M
categories, we divided EMs as two separate groups, EM1 (with the
number of EMs ,3) and EM2 (with the number of EMs $3),
according to the comparable survival outcomes between patients
with the number of 1 and 2 EMs and the distinct survival
outcomes between patients with the number of 2 and $3 EMs.
First, we compared the survival curve between patients with
EM1 and T stage. The Kaplan-Meier plots showed a good
discriminatory ability between patients with pT4a stage and
patients with EM1 (5-year survival rate 48.8% vs. 32.6%,
P=0.002), also between patients with EM1 and those with T4b
stage (5-year survival rate 32.6% vs. 23.4%, P=0.016) (Fig. 3A).
Secondly, when we compared the survival outcomes between
patients with EM1 and N stage, the overall survival rate of patients
with EM1 was found almost comparable to that of patients with
N3 stage (5-year survival rate 31.3% vs. 32.6%, P=0.437) and was
found significant worse than that of patients with N2 stage (5-year
survival rate 32.6% vs. 44.1%, P=0.039) (Fig. 3B). Thirdly, when
we investigated the possible origination of EM2 from peritoneal
seeding, we found that the overall survival rate of patients with
EM2 showed similar to that of aforementioned 106 cases of stage
IV patients. The 5-year survival rate was 6.8% and 5.6%,
respectively (P=0.896) (Fig. 3C).
Furthermore, we realized that 78.8% (141 of 179) of the EMs
was mainly found in stage III patients, with 103 cases of EM1 and
38 cases of EM2. In order to investigate the incidence and
influence of EM1 in stage III patients, we analyzed the survival
outcomes with and without consideration of EM1 as N3. Without
Table 1. Correlation between Extranodal Metastasis and
clinicopathological factors in gastric carcinoma patients with
potential radical resection.
Variable Extranodal Metastasis P value
Positive (%)
N=179
Negative (%)
N=1164
Gender 0.426
Male 125 (13.9) 777 (86.1)
Female 54 (12.2) 387 (87.8)
Age (year) 0.674
,60 97 (12.8) 662 (87.2)
$60 82 (14.0) 502 (86.0)
Tumor location ,0.001
Proximal 96 (13.3) 628 (86.7)
Distal 62 (10.9) 505 (89.1)
Total 21 (40.4) 31 (59.6)
Tumor size (cm) ,0.001
#5.0 78 (9.8) 714 (90.2)
.5.0 101 (18.3) 450 (81.7)
Histological grade ,0.001
Well/Moderately
differentiated (G1+G2)
38 (7.6) 465 (92.4)
Poorly differentiated (G3) 97 (16.9) 476 (83.1)
Undifferentiated (G4) 44 (16.5) 223 (83.5)
Lymphatic/Venous invasion ,0.001
No 146 (11.8) 1096 (88.2)
Yes 33 (32.7) 68 (67.3)
Depth of invasion
(AJCC 7th edition)
,0.001
T1 0 (0) 118 (100.0)
T2 4 (2.3) 167 (97.7)
T3 31 (12.2) 223 (87.8)
T4a 120 (17.8) 555 (82.2)
T4b 24 (19.2) 101 (80.8)
Nodal status
(AJCC 7th edition)
,0.001
N0 24 (5.2) 440 (94.8)
N1 37 (13.9) 230 (86.1)
N2 43 (13.1) 285 (86.9)
N3 75 (26.4) 209 (73.6)
TNM staging
(AJCC 7th edition)
,0.001
Stage I 2 (1.0) 190 (99.0)
Stage II 36 (8.8) 372 (91.2)
Stage III 141 (19.0) 602 (81.0)
doi:10.1371/journal.pone.0019557.t001
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stage IIIA, 37 cases of stage IIIB, and 39 cases of stage IIIC
patients. The survival curves were shown in Fig. 4A, in which the
survival difference in each substage was confused (P=0.991).
When we treated the EM1 as N3 patients, the distribution of stage
III was changed as 1 case of stage IIIA, 27 cases of stage IIIB, and
75 cases of stage IIIC patients. The survival curves were shown
discriminatory in each substage (P=0.023) (Fig. 4B).
In terms of the results aforementioned, different survival
outcomes based on the T, N and M stage were compared among
the following 4 redefinitions of the T, N and M categories: A, the
7th edition TNM definition without considering EMs; B,
redefinition of T stage with EM1 treated as TEM stage; C,
redefinition N stage with EM1 treated as N3 stage; D, redefinition
of M stage with EM2 treated as M1. The performance of the 7th
edition TNM staging systems with redefinitions of the T, N, and M
categories was assessed by the linear trend X
2, likelihood ratio X
2,
and the AIC tests, which was described in Table 3. Compared
with the 7th edition staging system without consideration of EMs,
the redefinition of T stage treated with EM1 as TEM stage,
redefinition of N stage with EM1 treated as N3 stage and
redefinition of M stage with EM2 treated as M1 stage all had
higher linear trend X
2 scores and likelihood ratio X
2 scores, and
lower AIC value, which represented the optimum prognostic
stratification, together with better homogeneity, discriminatory
ability, and monotonicity of gradients. (Table 3)
Discussion
Dependent on the pathological examination, a large variation in
the incidence of EMs has been reported in previous studies,
ranging from 10 to 28% of cases [1,2], mainly due to less caution
about this special type of cancer deposit and its prognostic value.
In the present study, we investigated the clinical parameters and
the prognostic value of EMs in a group of patients who underwent
potentially radical resection for gastric carcinoma, in which we
found that the incidence of EMs was 179 (13.3%) in 1343 patients.
The results revealed that the presence of EMs had a significant
correlation with the total gastric carcinoma, larger tumor, poorly
and undifferentiated carcinoma (G3/G4), lymphatic/venous
invasion, deeper tumor invasion (T4a and T4b) and more number
of lymph node metastases (N3), which were proven with worse
survival outcomes. In multivariate analysis, present of EMs
maintained as an independent prognostic factor for gastric
carcinoma patients with poor postoperative survival
(HR=1.412, 95%CI=1.151–1.731, P,0.001). This phenome-
non is consistent with the finding that EMs showed a close
correlation with cancer aggressiveness reported in previous studies.
While in previous studies, the patients who were found peritoneal
seeding in the operation were also enrolled and investigated [1,2].
In terms of the 7th edition UICC staging system of gastric
carcinoma, the type of EMs implanted on peritoneal surfaces are
clearly deemed as distant metastases (stage IV). So our study
mainly investigated the classification of EMs in patients underwent
potential radical resection and excluded patients with obvious
peritoneal seeding revealed during operation. Firstly, we found
that the survival outcomes were similar between patients with the
number of 1 and 2 cases of EMs and distinct with patients with $3
cases of EMs, which may indicate different origin and classification
of this type of metastasis. Secondly, we divided EMs into two
separate groups (EM1 and EM2) according to aforementioned
distinct survival outcomes and investigated the possible classifica-
tion. In T stage, we found that the 5-year survival rate was
different among patients with T4a, EM1 and T4b. In N stage, the
5-year survival rate of patients with EM1 was comparable to those
of N3 stage and was worse than those of N2 stage. In M stage, the
result revealed that patients with EM2 had a comparable survival
with those of M1stage. Furthermore, with the consideration of
EM1 mainly in stage III patients, we investigated the influence of
EM1 in each substage of stage III patients. The results also
supported that EM1 should be considered as N3 stage, if not, the
survival outcomes will be confused in each substage. Finally, we
validated our results utilizing the linear trend X2, likelihood ratio
X2, and the AIC tests to confirm the homogeneity, discriminatory
ability, and monotonicity of gradients of our novel classification.
Compared with the 7th edition TNM staging system without
consideration of the EMs, the new categories for N3 and M1 stage
demonstrated that they performed better homogeneity, discrim-
inatory ability, and monotonicity of gradients.
Although little evidence is available on the prognostic value of
EMs in gastric carcinoma patients, the presence of EMs was
incorporated in the TNM staging manuals in 1997 for the first
time, in which EMs were deemed as T or N stage in terms of
their shape [3]. The shape of tumor deposits is, however, not
sufficient to consistently distinguish different types of tumor
involvement of the perivisceral fat [14]. In our opinions,
classification of EMs based on their shapes is relatively
subjective, insufficiently validated, and difficult to clinical
Table 2. Univariate and multivariate survival analysis of clinic-pathologic variables in 1343 cases of gastric carcinoma patients with
potential radical resection.
Variables Univariate analysis Multivariate analysis
HR 95%CI P value HR 95%CI P value
Gender (female vs. male) 0.962 0.814–1.136 0.645
Age (year), ($60 vs. ,60) 1.433 1.226–1.675 ,0.001 1.468 1.254–1.719 ,0.001
Location (distal/proximal/total) 0.749 0.646–0.868 ,0.001 0.720 0.625–0.829 ,0.001
Size (cm) (.5 vs. #5) 2.110 1.804–2.468 ,0.001 1.601 1.365–1.878 ,0.001
Differentiation (G3/G2/G1) 1.257 1.133–1.393 ,0.001 1.184 1.061–1.321 0.003
Lymphatic/Venous invasion (Yes vs. No) 2.038 1.408–2.832 ,0.001 1.814 1.319–2.445 ,0.001
EM (Positive vs. Negative) 2.362 1.949–2.862 ,0.001 1.412 1.151–1.731 ,0.001
T (T4b/T4a/T3/T2/T1) 1.811 1.654–1.984 ,0.001 1.478 1.338–1.632 ,0.001
N (N3/N2/N1/N0) 1.650 1.538–1.769 ,0.001 1.417 1.311–1.531 ,0.001
doi:10.1371/journal.pone.0019557.t002
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e19557Figure 2. Prognostic significance of extranodal metastasis (EM) on overall survival rate of the gastric carcinoma patients
underwent curative surgery. 2A: A positive EM was significantly associated with a shorter survival time (P,0.001). 2B: Overall survival curves of
gastric carcinoma patients stratified by EM number (0, 1, 2, $3), (P,0.001, P=0.337, P=0.001, respectively).
doi:10.1371/journal.pone.0019557.g002
Figure 3. Comparison of survival curves between EMs and the T, N, M stages. 3A: Overall survival curves showed different outcomes
among patients with T4a, EM1 and T4b (P=0.002 and 0.016, respectively). 3B: Overall survival of patients with EM1 was worse than those of the N2
stage and was comparable to those of the N3 stage (P=0.039 and 0.437, respectively). 3C: Patients with EM2 had a comparable overall survival with
those of the M1 stage (P=0.896).
doi:10.1371/journal.pone.0019557.g003
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should not be classified on the basis of the shape but according
to their origin [14,15]. Furthermore, in our present study, we
demonstrated that the prognosis of patients with EM1 were
distinct to neither T4a nor T4b patients, which indicated that
the EMs should be not classified into T stage. In the 7th edition
system, the classification of EMs was revised and updated to
either to N or M stage although it was still relatively ambiguous
[5]. Tanaka et al. revealed that the extranodal invasion was a
significant risk factor for peritoneal metastasis in gastric
carcinoma that EMs maybe indicated to M category [1]. Puppa
et al. suggested that such tumor extension represented peritoneal
seeding from either the primary tumor or metastatic lymph
nodes and may rather be included in the M category for staging
purposes as they represented in-transit metastases, both in
colorectal cancer and other adenocarcinomas such as gastric,
biliary duct and pancreatic carcinomas [14,16]. For the aspect of
clinical practice, one of the main objectives of the TNM
classification is to provide prognostic information useful for
deciding the best treatment options for the patients, stratifying
them into groups that are prognostically and therapeutically
similar [17]. In our study, we intended to incorporate the EMs
into TNM staging system according to its prognostic information
which differed with previous proposals. Although previous study
has demonstrated that the number of EMs was correlated with
poor prognosis of gastric carcinoma [2], in our study number of
EMs, for the first time, was taken into account for classification
of TNM staging. To validate the feasibility of our assignment for
EM1 and EM2, methods of linear trend X2, likelihood ratio X2,
and the AIC tests were used. According to Ueno et al. [18], the
performance of the staging system can be evaluated as
homogeneity within subgroups, discriminatory ability between
different groups, and monotonicity of gradients shown in the
correlation between stages and survival rates. In our study, the
new categories of EM1 and EM2 incorporating into N3 and M1
staging performed better homogeneity (higher likelihood ratio
X2 score), discriminatory ability, and monotonicity of gradients
(higher linear trend X2 score). More importantly, the new
categories also showed smaller AIC value, representing the
optimum prognostic stratification and indicating the smallest loss
of information for predicting outcome. These results demon-
strated better prognostic stratifications of our assignment for
Figure 4. Comparison of survival curves among 103 cases of stage III patients with EM1 before and after consideration of EM1. 4A:
Patients with EM1 had a comparable overall survival curves among each substage when EM1 was ignored (P=0.991). 4B: Patients with EM1 had a
distinguishable overall survival curves among each substage when with the consideration of EM1 as N3 stage (P=0.023).
doi:10.1371/journal.pone.0019557.g004
Table 3. Definitions of T, N and M categories and their impact on the prognostic value of staging.
Category Definition Subgroups Linear Trend X
2 Likelihood Ratio X
2 *AIC
A 7th ed. T stage (n=1343) T1, T2, T3, T4a, T4b 171.755 201.840 8556.400
7th ed. N stage (n=1343) N0, N1, N2, N3 184.258 194.901 8547.653
7th ed. M stage (n=1503) M0, M1 112.316 133.065 10488.061
B Number of 1 and 2 EMs (EM1)
treated as TEM stage (n=1343)
T1, T2, T3, T4a, TEM,T4b 201.580 235.795 8515.847
C Number of 1 and 2 EMs (EM1)
treated as N3 stage (n=1343)
N0, N1, N2, N3 235.104 247.322 8508.678
D Number of $3 EMs (EM2)
treated as M1 stage (n=1503)
M0, M1 153.143 179.471 10421.502
*AIC=Akaike information criterion;
doi:10.1371/journal.pone.0019557.t003
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consideration of EMs.
We acknowledge several limitations in this study. Our sample
population is from a single institution experience and relatively
small compared with the worldwide gastric cancer collaboration
database, and is based on a retrospective study. While the
strengths of this study are that the surgical procedures, pathologic
examinations, and patient follow-up were uniform throughout the
entire study period. Cancer staging is a dynamic process. As our
understanding of cancer biology improves, the TNM staging
system will need to be revised accordingly. Our present study
demonstrated the EMs as an important prognostic factor and for
the first time intended to incorporate it into N3 or M1 staging
according to its number retrieved in postoperative samples in
patients with gastric carcinoma.
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